Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS)
The trial failed to meet its primary endpoint of complete remission (CR) rateCR rate was 53% higher in eprenetapopt with...